KEY NEW DATA SETS DISCUSSED IN THIS ISSUE
Cavo M et al. Bortezomib (Velcade)-thalidomide-dexamethasone (VTD) vs thalidomide-dexamethasone (TD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM). Proc ASH 2007;Abstract 73.
Fenaux P et al. Azacitidine (AZA) treatment prolongs overall survival (OS) in higher risk MDS patients compared with conventional care regimens (CCR): Results of the AZA-001 phase III study. Proc ASH 2007;Abstract 817.
Fisher RI et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24(30):4867-74. Abstract
Hillmen P et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25(35):5616-23. Abstract
Hochhaus A et al. IRIS 6-year follow-up: Sustained survival and declining annual rate of transformation in patients with newly diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) treated with imatinib. Proc ASH 2007;Abstract 25.
Hulin C et al. Melphalan-prednisone-thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients 75 years with multiple myeloma compared with melphalan-prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01/01. Proc ASH 2007;Abstract 75.
Kantarjian H et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial. Blood 2007;109(12):5143-50. Abstract
Orlowski RZ et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: Combination therapy improves time to progression. J Clin Oncol 2007;25(25):3892-901. Abstract
Rajkumar SV et al. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern Cooperative Oncology Group. Proc ASH 2007;Abstract 74.
Richardson P et al. Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) in patients with relapsed or relapsed/refractory multiple myeloma (MM): Preliminary results of a phase II study. Proc ASH 2007;Abstract 2714.
San Miguel JF et al. MMY-3002: A phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma. Proc ASH 2007;Abstract 76.
Van Oers MH et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial. Blood 2006;108(10):3295-301. Abstract
CONTENT VALIDATION AND DISCLOSURES
Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the Research To Practice scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — Dr Steensma had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr O’Brien — Advisory Committee: Biogen Idec, Eli Lilly and Company, Gemin X Pharmaceuticals Inc; Consulting Agreement: Genta Inc; Paid Research: Berlex Inc, Biogen Idec, Bristol-Myers Squibb Company, Eli Lilly and Company, Gemin X Pharmaceuticals Inc, Genentech BioOncology, Genta Inc, Novartis Pharmaceuticals Corporation. Dr Orlowski — Advisory Committee: Amgen Inc, Celgene Corporation, Millennium Pharmaceuticals Inc, Ortho Biotech Products LP. Dr Maloney — Advisory Committee: Biogen Idec, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Pharmion Corporation, Roche Laboratories Inc.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
| Table of Contents | Top of Page |
EDITOR
Neil Love, MD
INTERVIEWS
Susan M O’Brien, MD
- Select publications
Robert Z Orlowski, MD, PhD
- Select publications
David P Steensma, MD
- Select publications
David G Maloney, MD, PhD
- Select publications
Hematologic Oncology Update:
A CME Audio Series and Activity
